أفضل الروماتيزم - توب -260 أطباء

طبيب ذو خبرة في التحكم في التمثيل الغذائي لمرضى السكري وارتفاع ضغط الدم ودبلوم في أمراض السكر. المدير الطبي الحالي لـ GIOSTAR Mexico في Los Algodones Mexicali Baja California منذ عام 2017. تخرج من جامعة Guadalajara المستقلة ولديه خبرة في قبول المرضى والخدمات الطبية الخارجية وحالات الطوارئ في العديد من المستشفيات الخاصة.

دكتور طبي من كلية الطب بجامعة أنقرة. تخصص في الطب الباطني (2008) وأمراض الروماتيزم (2012) من مستشفى أنقرة نوموني للتدريب والبحوث. لديه خبرة في مستشفى أنقرة نوموني للتدريب والبحوث ، ومستشفى كاستامونو للدكتور منيف إسلام أوغلو ، ومستشفى أنقرة عبد الرحمن يورتسلان للأورام ، ومستشفى كوجالي ديرينس للتدريب والبحوث.

Biography

Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:

• Oncology care and treatment for chemotherapy, hormonal therapy, immune therapy, and target therapy
• Breast cancer
• Solid tumor diagnosis
• Digestive cancer
• Gynecological cancer
• Lung cancer
• Genitourinary cancer
• Sarcoma

Awards & Achievements

• Award from Himaya Foundations and University of Sharjah

Research & Publications

• Clinicopathological Features of Gastric Cancer in a Cohort of Gulf Council Countries' Patients: A Cross-Sectional Study of 96 Cases. Journal of Oncology Research Reviews & Reports Volume 2(2): 1-3.
• The Burden of Gynecologic Cancers in the UAE. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The Emirates Oncology Task Force Clinical Practice Guideline on Screening for SARS-CoV-2 in Asymptomatic Adult Cancer Patients Before Anti-Cancer Therapy. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. Humaid Al-Shamsi, Humaa Darr, Ibrahim Abu-Gheida , Jawaher Ansari, Martine, Mehdi Afrit, Mohamad H Masri, Mohamed Abuhaleeqa. Gulf J Oncology 2020 Jan;1(32):71-87.
• Primary Bone Lymphoma: Tunisian Multicentric Retrospective Study About 32 Cases. Ben Ayed C, Laabidi S, Said N, Afrit M, Ben Ahmed S, Boussen H. Tunis Med. 2018 May;96(5):269-272.
• First Site of Recurrence After Breast Cancer Adjuvant Treatment in the Era of Multimodality Therapy: Which Imaging for Which Patient During Follow-up? Nesrine M, Mehdi B, Houda EB, Soumaya L, Mehdi A, Bechir Z, Hamouda B. Breast Dis. 2017 Nov 21

Professor Carlo Selmi is leading the Rheumatology and Clinical Immunology Unit at Humanitas Research Hospital. 

Since 2009, he is the responsible of the Autoimmunity and Metabolic Laboratory, dedicated to the study of the possible mechanism linked to the progression of autoimmune diseases. 

The research focuses on four main areas: 

• - The epigenetic mechanisms that regulate the environment-genomic interface by influencing the susceptibility and the phenotype of chronic autoimmune and inflammatory diseases in the model of discordant monozygotic twins for disease. To date, the laboratory has biological sample of discordant couples for numerous diseases.
• - The target antigens of autoimmunity modifications that affect the development of the course of autoimmune diseases. In particular, the laboratory studies the post-translational modifications of joint collagen in rheumatoid arthritis.
• - The prevalence of non-organ autoantibodies, such as anti-nucleus and anti-ENAs and disease specific autoantibodies, such as anti-citrulline and anti-endomysium in a non-specific population of health adults and the significance of the positive founds over time.
• - Gender medicine in real-life, through the analysis of administrative databases.

The team holds dedicated clinics also for, spondiloarthritis and connetcive tissue disease, and it is active in articular ultrasound, videocapillaroscopy, arthrocenthesis and joint injection of steroid or hyaluronic acid.  The Division includes an inpatient clinic for complex cases. All group members are fluent in spoken and written English

Current Teaching Activity: Professor Selmi works as Assistant Professor of Rheumatology at the University of Milan since 2006. Furthermore, he holds a joint appointment as Assistant Professor of Medicine at the Division of Rheumatology of the University of California at Davis since 2005.

He is member of the American College of Rheumatology, American Association of Allergists and Immunologists, and the Italian Society of Rheumatology. He serves on the International Group for Research on Psoriatic Disease (GRAPPA) and the working group for autoantibody standardization within the ACR (ASC).

Publications: Selmi C[Author] - Search Results - PubMed (nih.gov)